Parent, Pediatric Oncology, Radiotherapy
Conditions
Brief summary
Pediatric radiotherapy is an anxiety-provoking situation that can, on one hand, impair the child's cooperation and require sedation, and on the other hand,burden the care pathway by generating significant anxiety in both the child and their parents. Companion robots represent an innovative avenue for patient support, but they have never been evaluated in the context of radiotherapy. This study examines the effect of MIROKI, the first social robot capable of communication through a Large Multimodal Model (LMM), on children's state anxiety during radiotherapy. An experimental single-case design (SCED) will compare phases with and without the robot (withdrawal/reversal), both in the waiting room and in the irradiation bunker. The primary outcome variable is anxiety, assessed in several ways: through questionnaires at the beginning and end of treatment; through an objective measure of cardiac activity (heart rate in bpm) during the radiotherapy session, with or without the MIROKI robot; and through an observational grid assessing the child's behavior. The intensive repeated measure (bpm) constitutes the preferred variable in this SCED design, while behavioral observation and anxiety questionnaires will support interpretation. The results could pave the way for reducing sedation and improving the overall care pathway in pediatric radiotherapy.
Interventions
None listed
Sponsors
Institut du Cancer de Montpellier - Val d'Aurelle
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Children aged 4 to 18 years, distributed across the following age groups: 4-7 years, 8-12 years, and 13-18 years. 2. Child with an indication for radiotherapy treatment at ICM. 3. Child who speaks French. 4. Child accompanied by a parent or legal guardian who agrees to participate in the study and provide consent. 5. Child covered by the French national health insurance system.
Exclusion criteria
6\. Child with a diagnosed neurodevelopmental disorder as a comorbidity. 7. Child with postoperative cognitive sequelae that make interaction during care difficult (e.g., language impairment). 8. Total body irradiation. 9. Child under legal protection, unable to express assent, or presenting major difficulties in understanding the study information. Parent Inclusion Criteria 1. Parent of a child enrolled in the study. 2. Able to speak French. 3. Willing to participate in the study. Parent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the immediate intra-individual effect of MIROKI on a physiological marker of anxiety in children undergoing radiotherapy. | During the treatment, across the 6 radiotherapy sessions | The child's anxiety level measured through an objective assessment of heart rate (bpm sensor). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the immediate intra-individual effect of MIROKI in children on: Psychological distress level | administered before the start of treatment and after completion of treatment | Distress questionnaire (PedsQL 3.0 Cancer Module score, Varni et al.) |
| Evaluate the immediate intra-individual effect of MIROKI in children on development of attachment and reassurance | Before, during, and after treatment | Daily distress VAS (Peds-DTRS score, Patel et al., 2011, 2021) and standardized real-time observation using an observational grid. |
| Evaluate the satisfaction with care (radiotherapy at ICM) at the end of treatment | At the end of treatment | Post-treatment interview (thematic and lexico-metric analysis). |
| Evaluate the impact of MIROKI on the radiotherapy process: Setup time during sessions in the radiotherapy room | From the beginning to the end of the treatment course | — |
| Evaluate the impact of MIROKI on parents: - Anxiety level - Satisfaction with care at the end of treatment - Experience of the radiotherapy process at the end of treatment | Before the start , during and after the treatment, | * Anxiety score (GAD-7, Spitzer et al., 2006) * Parent-child relationship quality score (CPRS, Pianta et al., 1992) During treatment: \- Daily anxiety VAS (daily DT score, Leclair et al., 2016; NCCN, 2025) After treatment: \- Assessment of the radiotherapy experience and satisfaction with care with the robot, using the parent interview grid |
Countries
France
Contacts
CONTACTAurore MOUSSION
PRINCIPAL_INVESTIGATORJulien, Welmant
ICM Co. Ltd.
Outcome results
None listed